, of which 515 had Stage 3 CKD. These 515 patients had significantly higher peripheral systolic BP (127 6 16 versus 125 6 15 mmHg, P ¼ 0.01) and central PP (43.0 6 11.4 versus 39.7 6 10.0 mmHg, P <0.001) than the control group (eGFR >60 mL/min/1.73 m 2 ). Propensity score matching allowed the creation of 500 pairs with similar clinical characteristics. In this matched cohort, central BPs were similar in Stage 3 CKD patients compared with controls (central PP 42.9 6 11.3 versus 43.7 6 11.3 mmHg, P ¼ 0.3). Multivariate analysis using data from all patients also found that the higher central hemodynamic readings found in Stage 3 CKD patients disappeared after adjusting for comorbid conditions. In a subset of 609 participants in whom albuminuria levels were measured, urine albumin excretion was not independently associated with higher central hemodynamic indices.
Conclusion:
In this large cohort from the general population, early CKD and albuminuria was not independently associated with detrimental central hemodynamic parameters.
Keywords: albuminuria, central blood pressure, central pulse pressure, chronic kidney disease, pulse wave analysis
I N T R O D U C T I O N
Chronic kidney disease (CKD) is a worldwide health burden with increasing prevalence and associated cardiovascular (CV) morbidity and mortality [1] . The treatment of CV risk factors, mainly hypertension, remains the cornerstone of CKD management. Isolated systolic hypertension is highly prevalent in CKD, and it is caused, at least in part, by the impact of aortic stiffness on central blood pressures (BPs). Indeed, aortic stiffness is strongly associated with detrimental central hemodynamic parameters and CV mortality in various populations, including advanced CKD and end-stage renal disease (ESRD) [2] [3] [4] [5] [6] [7] .
The nature of the association of central hemodynamic BPs with advanced CKD or ESRD is well described. Advanced CKD, through various mechanisms, such as endothelial dysfunction, accumulation of uremic toxins such as advanced glycation end-products [8] and CKD-related abnormal mineral disorder [9] , leads to aortic stiffness and increased aortic BPs. Whether the same can be said, although to a lesser degree, of mild-to-moderate CKD (KDIGO Stage 3) remains to be elucidated. Aortic stiffness could also lead to CKD through a higher Nephrol Dial Transplant (2017) 32: 976-983 doi: 10.1093/ndt/gfw059 Advance Access publication 13 April 2016 pulse pressure (PP) transmission into the microcirculation of the kidneys, leading to organ damage and dysfunction [10] . While most studies have attempted to determine the impact of early CKD on arterial stiffness, sparse data exist on the association between early CKD and central hemodynamic parameters, and whether this association is independent of important comorbid conditions and peripheral BP, or related to shared confounding factors such as advanced age, hypertension and diabetes [11] [12] [13] [14] [15] [16] [17] [18] [19] . If metabolic complications in early CKD directly promote an increase in central BP and vascular stiffness, the early treatment of such conditions could be considered as potential therapeutic targets of cardiovascular and renal protection. As there is ongoing debate as to how aggressively classical and non-classical risk factors for CV disease should be treated in CKD, there is a need to study the impact of early CKD on central BPs using large populational cohorts.
We used multiple complementary approaches to study the association between Stage 3 CKD and central hemodynamic parameters by examining the data from the CARTaGENE (CaG) cohort, a large randomly selected cohort from the general population of Québec.
M A T E R I A L S A N D M E T H O D S

Study design and population
This study is a cross-sectional analysis of CaG, a populationbased survey designed to investigate social, environmental and medical determinants of chronic diseases. The CaG cohort is comprised of individuals aged 40-69 years old from the province of Québec (Canada). Details of the survey methods and sampling results have previously been published [20] [21] [22] . To summarize, participants were randomly selected between July 2009 to October 2010 from the population of four urban regions (Montreal, Québec City, Sherbrooke, Saguenay) using the governmental health insurance database for identification. Data were collected from 20 004 individuals, which represents 1% of the 40-69 years old population of the province of Québec. All participants provided signed informed consent, and the study adhered to the Declaration of Helsinki. This study has been approved by all appropriate Ethics Committees. For the specific purposes of the present study, participants with available pulse wave analysis data were selected, provided the overall quality of the recording was adequate as defined by the manufacturer (operator index !80%). Participants without serum creatinine measurements or any other missing covariables were excluded. Furthermore, considering the strong evidence regarding increased central hemodynamic parameters in advanced CKD and dialysis [5] [6] [7] , individuals with KDIGO Stages 4-5 CKD [23] and/or a previous history of dialysis or kidney transplantation were excluded.
Measures and definitions
Participants of CaG were evaluated during a single clinic visit with health and lifestyle questionnaires, brachial BP measurements and central pulse wave analysis, with blood samples subsequently collected. Estimated glomerular filtration rate (eGFR) was calculated from IDMS-calibrated serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [24] . CKD Stage 3 includes all participants with an eGFR 30-60 mL/min/1.73 m 2 in accordance with the KDIGO classification. Albuminuria measurements were available in a subset sample of CaG participants, precluding further characterization of CKD using 'A' categories. The control group consisted of individuals with eGFR >60 mL/min/1.73 m 2 [11, 25] . Brachial BP were measured in accordance with recommended guidelines after 10 min of seated rest in an isolated room, with prior upper arm measurement to determine adequate BP cuff size [26] . Averages of three measurements performed at 2-min intervals using an automated oscillometric device (BP monitor, Omron 907L; Omron Lake Forest, IL) were recorded. PP was defined as the difference between systolic (SBP) and diastolic blood pressures. Diagnosis of diabetes was defined as: glycosylated hemoglobin A1c (HbA1c) !6.5% and/ or fasting glucose !7.0 mmol/L and/or non-fasting glucose !11.1 mmol/L and/or use of hypoglycemic agents [27] . The presence of hypertension and CV disease (previous myocardial infarct, angina, stroke or transient ischemic attack) were selfreported by the participants. All medication taken by each participant was recorded after verification for treatment adherence by the nurse performing the questionnaire. Albuminuria was measured in a subset of the overall cohort [28] .
Central pulse wave analysis
Central pulse wave analysis was recorded by trained operators with applanation tonometry using a generalized transfer function (SphygmoCor Px, AtCor Medical, Lisle, IL) [29] . At least two recordings were obtained for each subject after a 10-min seated rest in a quiet room, with data subsequently averaged. These recordings were obtained in the same sitting as brachial BP measurements. Quality of recordings was assessed using the operator index, a composite of quality indices (average pulse height, diastolic variation and shape variation). Participants with recordings failing to meet the minimally acceptable operator index (80%) were excluded from further analysis, in accordance with manufacturer's instructions. The following parameters were derived from central pulse wave analysis ( , which represents the additional load to which the left ventricle is subjected because of backward wave reflection and depends on the cardiac cycle (thus heart rate), the velocity of the pulse wave and the amplitude of the reflected wave. The PP amplification, augmented pressure and augmentation index are considered indirect markers of arterial stiffness.
Statistical analyses
To compare central hemodynamic parameters between Stage 3 CKD and control patients, propensity score matching was performed. This analysis allows direct unadjusted comparison of matched patients, and minimizes confounding due to
measured and unmeasured differences between groups [30] . Furthermore, it eliminates the potential bias due to possible non-linear relationships between central hemodynamic parameters and certain continuous covariables, such as age and body mass index (BMI). The propensity score was calculated using a binary logistic regression and the following covariables: age, gender, mean arterial pressure, heart rate, BMI, presence of hypertension, diabetes and CV disease, past or present smoking, total cholesterol, high-density lipoprotein (HDL) cholesterol, uric acid and use of statin, b-blockers, renin-angiotensin system blockers, calcium channel blockers and diuretics. These covariables were pre-specified based on the literature and biological plausibility and are related to the exposure or the outcome, as inclusion of both types of variables has been shown to decrease the variance of the exposure effect without increasing bias [31] . Subsequently, a nearest-neighbor 1:1 match (without replacement) was performed using caliper widths equal to 0.2 of the standard deviation of the logit of the propensity score [32] . Absolute standardized differences <10% between each covariate were indicative of appropriate balance between the matched groups [33] .
To complement the propensity score, a secondary analysis was performed on the overall cohort of Stage 3 CKD and the control group. Univariate analyses of variance were performed and estimated marginal means were calculated using general linear models with adjustments for all the covariates included in the calculation of the propensity score.
Finally, multivariate linear regressions were used to evaluate the association between albuminuria and central BP indices, with adjustments for all covariates listed above. Albuminuria levels were log-transformed before analysis to account for the skewed distribution of this parameter. As only 25 of 609 participants with available albuminuria measurement had moderately elevated albuminuria (defined as a urine albumin-to-creatinine ratio between 3.4 and 34 mg/mmol of creatinine), analysis of albuminuria using as a dichotomous outcome could not be performed.
Normally distributed continuous data are presented as mean 6 standard deviation and compared with Student t-tests while non-normally distributed data are expressed as median (interquartile range; IQR) and compared using Mann-Whitney Utests. Categorical data were compared with Pearson's v 2 test. All P-values <0.05 were considered significant. Analyses were performed with IBM SPSS Statistics software, version 22.0 (IBM Corp., Armonk, NY).
R E S U L T S
Characteristics of the overall cohort
Of the 20 004 CaG study participants, 14 158 had pulse wave analysis of acceptable quality. Individuals without serum creatinine measurements (n ¼ 320), with missing covariate data (n ¼ 705), with an eGFR <30 mL/min/1.73 m 2 or history of hemodialysis and/or kidney transplantation (n ¼ 19) were excluded from analysis (Figure 2 ). Of the remaining 13 114 participants, 515 had Stage 3 CKD at the time of the survey. Participants with Stage 3 CKD had significant differences in baseline characteristics compared with the controls with eGFR >60 mL/min/ 1.73 m 2 ( Table 1 ). They were older [age of 63 (IQR 57-67) versus 53 (48-61) years, P < 0.001], and had a higher prevalence of hypertension (46 versus 24%, P < 0.001), diabetes (21 versus 9%, P < 0.001) and CV disease (11 versus 6%, P < 0.001). Stage 3 CKD patients also had significantly higher peripheral SBP (127 6 16 versus 125 6 15 mmHg, P ¼ 0.01) despite a higher use of all antihypertensive medication classes. Excluded individuals had similar baseline characteristics to the control group.
Comparison of unadjusted central hemodynamic parameters showed that Stage 3 CKD patients had significantly higher central PP (43.0 6 11.4 versus 39.7 6 10.0 mmHg, P < 0.001) and augmented pressure [11.6 (7.4-15.6) versus 10.4 (6.7-14.6) mmHg, P < 0.001; Table 2 ]. Central SBP, PP amplification and augmentation index were similar between the groups.
Propensity score matched cohort
Using the propensity score, we were able to match 500 of the 515 Stage 3 CKD individuals to 500 controls with similar age, size and comorbid conditions. Covariate balance was appropriate, apart from a slightly higher prevalence of CV disease in the CKD group (11 versus 9%, standardized difference 15.3%, P ¼ 0.02; Table 3 ). In this propensity score matched cohort, there were no significant differences in central SBP, central PP, augmentation index, PP amplification and augmented pressure between groups (Table 4) .
Adjusted central hemodynamic parameters
To complement the propensity score, a general linear model was also used to calculate adjusted central hemodynamic parameters on the entire cohort. Using this approach, Stage 3 CKD status was also not associated with increases of central SBP, central PP, augmentation index and augmented pressure (Supplementary data, Table S1 ). Only PP amplification was shown to be slightly but statistically higher in the presence of Table S2 ).
D I S C U S S I O N
This analysis of a large cohort of randomly selected individuals aged 40-69 years attempted to demonstrate an association between central hemodynamic parameters measured by pulse wave analysis and Stage 3 CKD. Using a propensity score matching procedure, Stage 3 CKD and control cohorts were created to directly compare central BP indices. In this analysis, central SBP, central PP, augmentation index, PP amplification and augmented pressure were similar between early CKD and control patients with matched peripheral BP. In secondary linear regression analyses using data from the overall cohort, adjusted central BP indices were also similar between Stage 3 CKD and control individuals. Only PP amplification was shown to be higher in CKD patients after adjustments with important covariables. Finally, using data from a subset of the overall CaG cohort with available albuminuria, it was demonstrated that urine albumin excretion levels are not associated with elevated central BP indices despite being associated with increased peripheral BP. The results of the present study argue against an independent association between detrimental central hemodynamic parameters and early CKD.
Uncertainty remains in regards to the association of increased central hemodynamic parameters with renal function in mild to moderate CKD (Stages 1-3) . Most studies have evaluated the impact of CKD on arterial stiffness (through measurement of the pulse wave velocity) but few have directly addressed the impact of CKD on central BP indices. Indeed, while some studies have suggested that in CKD Stages 1-3, a lower eGFR is associated with increased pulse wave velocity [10, 15] , others have found that the association of pulse wave velocity with eGFR could be explained by age and traditional CV risk factors [11] [12] [13] [14] 16] . The most comprehensive data on central BP comes from The Framingham Heart Study, which failed to identify an association between central PP, augmentation index, augmented pressure and renal function [11] . In contrast, it was shown that albuminuria is associated with higher central PP, , and could result in misclassification of CKD stages [34, 35] .
Central hemodynamic and arterial stiffness parameters are associated with CV events in high-risk patients [2, 3] and in patients with coronary artery disease [36] , hypertension [37] , advanced CKD [4] and ESRD [5, 6] . In addition, central SBP and PP appear to predict the occurrence of CV events and endorgan damage more accurately than brachial BP [38, 39] . A decreased PP amplification (representing a lower amplification of the pressure wave from central to peripheral arteries) has also been linked to adverse CV outcomes [40] . While the physiopathology of arterial stiffness and increased central hemodynamic parameters in moderate-to-severe CKD remains to be fully elucidated, vascular calcification [9, 41, 42] and CKD mineral bone disease appear to be important mediators. It has been shown that higher phosphate and osteoprotegerin [43, 44] as well as decreased klotho and fetuin-A [44, 45] are independently associated with increased arterial stiffness. Others have suggested that accumulation of advanced glycation products could also contribute to this phenomenon [8] . Increased central BP could also contribute to CKD progression. It is believed that as stiffness increases, the low resistance and impedance of afferent arterioles exposes the renal microcirculation to increasing pulsatile stress and wide variations of systolic and diastolic flows, leading to vasoconstriction and increased resistance [10, 46] . Stiffness also increases BP variability by decreasing baroreflex sensitivity and arterial wall elasticity, which could enhance renal flow pulsatility and vascular damage. More recently, it was suggested that aortic blood flow reversal caused by aortic stiffening could reduce the blood flow into the kidney [47] . Overall, these mechanisms progressively lead to parenchymal damage and structural remodeling, with subsequent loss of renal function. The results of our study suggest that in early stages of CKD, the central hemodynamic effects of arterial stiffness are not significant.
This study is noteworthy for several reasons when compared with the available literature. This is the largest study used to assess the impact of Stage 3 CKD on central hemodynamic parameters. Renal function was estimated using the CKD-EPI equation, which provides a more accurate estimation of GFR above 60 mL/min/1.73 m 2 . Peripheral and central BPs were 10.4 (6.7-14.6) 11.6 (7.4-15.6) <0.001
Values are expressed as mean 6 standard deviation. The control group consists of participants with eGFR >60 mL/min/1.73 m 2 .
CKD, chronic kidney disease; SBP, systolic blood pressure; PP, pulse pressure.
measured under strict conditions, with exclusion of recordings failing to meet strict quality criteria. Furthermore, the size of the cohort and quality of data collection allowed matching and adjustments for the use of all classes of antihypertensive medication, which are known to greatly impact central BP and arterial stiffness [48] . While all central hemodynamic parameters were similar between Stage 3 CKD and control patients in the primary analysis, a small (<1%) relative difference in PP amplification was found to be associated with CKD in the secondary analysis. However, the clinical relevance of this finding remains unknown. First, this finding was not found in the propensity score analysis, which is more suited to compare individual parameters, with less dependence on linearity assumption than regression analysis. Second, lower levels are usually associated with adverse CV outcomes and in this analysis, CKD patients had higher values than control subjects. Third, the large size of the present cohort provided statistical power to detect small differences in central parameters but with unknown clinical significance. This study has several limitations. First, selection bias cannot be excluded due to the voluntary nature of the survey and low participation rate. Only individuals 40-69 years old were studied, which may limit generalization to younger and older patients. Participants had a single measurement of serum creatinine, whereas multiple samplings are required for CKD diagnosis. Participants with eGFR >60 mL/min/1.73 m 2 were used as a non-CKD control group, although some individuals may have been classified as CKD Stages 1-2 if urinalysis and renal imaging were available. However, in the albuminuria sub-analysis (performed using data from a representative subset of CaG participants with similar characteristics to the overall cohort), this parameters was not associated with changes of central hemodynamic parameters. Our data cannot exclude the possibility that central BPs differ in more advanced Stage 3 CKD. Finally, the carotid-femoral pulse wave velocity, currently considered the best parameter to assess central arterial stiffness, was not measured in participants. However, it was our goal to assess the central hemodynamic consequences of early CKD, of which arterial stiffness is an important determinant.
To conclude, in this large cohort from the general population, Stage 3 CKD and albuminuria were not independently associated with detrimental central hemodynamic parameters. This suggests that the impact of kidney function on central BP . CKD, chronic kidney disease; SBP, systolic blood pressure; PP, pulse pressure. may only be manifest at more advanced stages of kidney disease, and raises questions as to the importance of specifically targeting these parameters in early CKD.
S U P P L E M E N T A R Y D A T A
Supplementary data are available online at http://ndt.oxford journals.org. 
C O N F L I C T O F I N T E R E S T S T A T E M E N T
The authors have nothing to disclose.
